News
- Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial 6/19/2012
-
Abbott Announces Initiation Of Phase 3 Study Of Elagolix In Patients With Endometriosis
6/5/2012
Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist.
-
Phase III Study: Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy
6/4/2012
Final results from PARAMOUNT, a Phase III study of ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company (NYSE: LLY).
-
Flu Shot During Pregnancy Shows Unexpected Benefits In Large Study
5/22/2012
Getting a flu shot during pregnancy provides unanticipated benefits to the baby, according to the authors of a large population-based study examining the issue.
-
HIV Vaccine Trials Network Opens Enrollment For Phase 1 Trial Of GeoVax Labs' Second Generation HIV Vaccine
5/22/2012
GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.
-
Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival
5/22/2012
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.
-
Breast Cancer Clinical Trial To Test Combination Of Heat Shock Protein Inhibitor And Hormonal Therapy
5/22/2012
Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. By Nicole Giese Rura
-
Generex Announces New Members Of Antigen Express Scientific Advisory Board For The AE37 Breast Cancer Vaccine
5/17/2012
Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine.
-
Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial
5/16/2012
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.
-
Inc Research Selects Transperfect’s Trial Interactive Technology As Its Electronic Trial Master File (eTMF) Solution
5/14/2012
TransPerfect, a leading provider of e-clinical technologies to the life sciences industry, recently announced that INC Research, a therapeutically focused clinical research organization (CRO), has selected Trial Interactive as its global electronic Trial Master File (eTMF) solution.